Search for content, post, videos

Modus Therapeutics announces positive Phase 1b data

Modus Therapeutics has announced positive top-line data from its lipopolysaccharide (LPS) provocation study, a key step in evaluating the potential of its lead asset, sevuparin, as a treatment for sepsis and other conditions with systemic inflammation. In this study, healthy volunteers received L
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.